| Autor: |
Ramos, Teresa Lopes, García-Guerrero, Estefanía, Caballero-Velázquez, Teresa, Rodríguez-Gil, Alfonso, Caracuel-García, Rocío, Nufer, Melanie, Robles-Frías, María José, Barbado, María Victoria, Pérez-Simón, José A. |
| Zdroj: |
Bone Marrow Transplantation; 20240101, Issue: Preprints p1-10, 10p |
| Abstrakt: |
In this study, we aimed to modify the immune response in the long term after allogeneic bone marrow transplantation (allo-BMT) by using the proteasome inhibitor ixazomib (IXZ) at the late stages of the post-transplant period. This approach facilitated the immune reconstitution after transplantation. IXZ significantly prolonged survival and decreased the risk of chronic graft-versus-host disease (cGvHD) in two different murine models without hampering the graft-versus-leukemia (GvL) effect, as confirmed by bioluminescence assays. Remarkably, the use of IXZ was related to an increase of regulatory T cells both in peripheral blood and in the GvHD target organs and a decrease of effector donor T cells. Regarding B cells, IXZ treated mice had faster recovery of B cells in PB and of pre-pro-B cells in the bone marrow. Mice receiving ixazomib had a lower number of neutrophils in the GvHD target organs as compared to the vehicle group. In summary, delayed administration of IXZ ameliorated cGvHD while preserving GvL and promoted a pro-tolerogenic immune response after allo-BMT. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink